The mdx mouse model of muscular dystrophy has a premature stop codon preventing production of dystrophin. This results in a progressive phenotype causing centronucleation of skeletal muscle fibers, muscle weakness and fibrosis and kyphosis.
Introduction
The hereditary degenerative genetic disease Duchenne muscular dystrophy (DMD) results from mutations in the dystrophin gene that prematurely terminate dystrophin protein synthesis and cause loss of functional protein. Dystrophin is a component of the dystrophin-glycoprotein complex (DGC) that anchors the contractile machinery of myocytes to the myofibre membrane (6, 7) . The absence of dystrophin leads to muscle cell weakness and deterioration, allegedly as a result of the breakdown in the normal architecture of the sarcolemma (6) .
Antisense oligonucleotides (AOs) have shown promise as a potential treatment of DMD. AOs alter RNA splicing, allowing protein truncating mutations to be excised from the mature dystrophin mRNA and production of a shorter Becker muscular dystrophy (BMD)-like protein. As such, the severe DMD phenotype can be converted to a milder BMD phenotype. BMD patients have mutations in which the reading frame is typically retained but internal sections of the gene are deleted (8) . This results in a partially functional dystrophin protein in which the N-and C-terminal ends are preserved (8) .
Exon skipping has been successfully induced in cells derived from the mdx mouse (12, 14, 15, 22 ) the golden retriever muscular dystrophy (GRMD) dog (16) and cultured myocytes from DMD patients (1, 19) . No counteractive immune response has been found with repeated, current AO administration methods, which provides a significant benefit (12) .
In mdx mice, increased contractile forces have been reported 3 to 4 weeks after a single injection of AOs directly into the tibialis anterior muscles. In addition, protein expression has been induced by 2OMeAOs in 2 to 4 week old mdx mice as well as in 6 month old mice (12) . In that study dystrophin persisted for up to 2 months, although another group found that AO-induced dystrophin expression is much more transient, possibly due to both a loss of AO and protein turnover (21).
To date, there have been no studies reporting either chronic administration of AOs in mice or studies reporting their effects in very old mdx mice, despite their skeletal muscles undergoing cycles of degeneration and regeneration, and showing pathology late in life closer to DMD dystrophinopathy (11, 17) . There is a need to apply AOs to a range Page 3 of 25 of muscles over an extended period of time in order to assess the functional changes in those muscles and extend the therapeutic applicability of these techniques.
Thus, the aims of this study were to determine changes in the extent of kyphosis in AOtreated mdx mice and in the structure and function of intercostal, latissimus dorsi, and diaphragm muscles following 15 once monthly, deep intramuscular injections of AOs into paraspinal muscles.
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Methods
Animals
Experiments were carried out on 3 groups of male mice (C57BL/10ScSn (C57): mdx sham treated: mdx AO treated). Mice were 2 months old at the beginning of the experiment and 18 months at the time of euthanasia. Animals were bred and housed at the 
Radiography and determination of Kyphosis Index
Once anaesthetised, adhesive tape was used to lightly secure the mice to a radiographic cassette before being radiographed as described previously (10) . The KI was calculated according to Laws & Hoey(10) .
Antisense oligonucleotides
The hair over the dorsum was clipped, and the skin cleaned with ethanol prior to AO injections. The mice were positioned in ventral recumbency and the injection sites were located in the paraspinal muscles adjacent and parallel to the thoracolumbar vertebrae. The 30 g needles were placed deep into the longissimus dorsi muscles, orientated in a cranial direction and kept as flat as possible. Evidence from preliminary experiments using injections of dye showed that the majority of the injectate remained within the longissimus dorsi muscles, but a small amount spread within the dorsal portion of the latissimus dorsi muscle, or sometimes into adjacent intercostal muscles. These variations may be due to the needle depth, or occasionally a small volume of injectate could travel via fascial planes to other muscle regions. This variation in distribution was unlikely to cause concern, as it is highly probable that each muscle plays a contributory role in the progression of kyphosis, and the latissimus and intercostal muscles were also evaluated in contractility studies. Three evenly spaced injections were administered on each side of the spine, to give a total of 6 µg of AO per mouse in a total volume of 40 µL.
The AO (M23D (+02-18) 
Contractility studies
Mice were anaesthetised at 18 months of age using pentobarbitone sodium 
Histology
Following contractility experiments, muscles were pinned onto cork at optimal length and then fixed sequentially in Telly's fixative (formaldehyde, glacial acetic acidethanol fixative, 72 hours), Bouin's solution (formaldehyde, glacial acetic acid-picric acid fixative, 24 hours) and 70 % ethanol, prior to paraffin embedding. Sections were cut at Dyes, Germany in saturated picric acid), a collagen specific stain. Fluorescent microscopy images were acquired using a digital camera (Q imaging Micropublisher 5.0 RTV) coupled to an epifluorescence microscope (Eclipse E600, Nikon, Japan). To grade collagen as a percentage of tissue area, four sections per tissue were photographed and analysed using AnalySIS (Soft Imaging System), then averaged. Additional 5 µm sections were stained with haematoxylin and eosin and viewed using bright field, with images acquired and analysed using the same equipment. Percentages of muscle fibres with centralised nuclei were determined in 200 fibres per muscle. All histological analysis was performed blinded to the strain of mouse or treatment.
Protein extraction and Western blotting
Protein was extracted from tissues and prepared for fractionation as previously 
Immunofluorescence
Muscles were snap frozen in isopentane that had been pre-chilled using liquid nitrogen. Dystrophin was detected on 6 µm muscle sections as described previously in Fletcher et al. (2006) , except that the Novocastra NCL-DYS2 primary antibody was used at a dilution of 1:25. Fluorescence was visualised and captured using a digital camera (Q imaging Micropublisher 5.0 RTV) coupled to an epifluorescence microscope (Eclipse E600, Nikon, Japan).
Statistics
Results are expressed as means ± S.E. Responses between the mdx and control strain were analysed using Student's unpaired t-tests or ANOVA for analysis of KI. P < 0.05 was considered statistically significant.
Results
Evaluation of long term AO administration
All mice tolerated the injection procedure well, with no adverse effects noted.
There were no significant differences in final body weights between the three groups (C57 control: 30.4 ± 1.0g, mdx sham treated: 31.4 ± 0.9g, mdx AO treated: 31 ± 1.0g).
Kyphotic Index
KI as a measure of spinal deformity was similar for all three groups at 6 and 8 months of age. The AO-treated mdx showed a tendency to a greater KI than sham treated mdx as the mice aged (and hence less thoracic deformity) with this reaching statistical significance at 10, 12, 16 and 18 months of age (Fig 1 and 2) . AO-treated mdx mice had a lower KI compared to C57 control mice from 10 to 18 months of age, however at 18 months, where a low KI is normally expected in mdx mice, there was no statistical significance between the mdx AO-treated and C57 mice.
Muscle contractility
There was a significant increase in weights of all mdx muscle preparations (sham and AO-treated) compared to wild type mice, however, there were no significant differences in muscle morphometry (optimal length (Lo), weight and width) between AO and sham treated mdx (data not shown). Whilst the mdx sham-treated latissimus dorsi, diaphragm and intercostal muscles were significantly weaker than C57 control muscles, there was no significant improvement in normalised twitch force or normalised tetanic forces in the latissimus dorsi, diaphragm and intercostal muscles of mdx mice treated with 1 µg AO (data not shown).
Histology
Of the four sham treated mdx muscles assessed, the diaphragm had the highest levels of fibrosis at 18 months old (P<0.05) as shown in Figures 3 and 4 . There was also a significant amount of fibrosis in sham-treated mdx latissimus muscles (P<0.05) when compared to C57 mice. The AO treatment significantly reduced the fibrosis in diaphragm and latissimus muscles in mdx (Figures 3 and 4) .
The characteristics of dystrophy, including variability in fibre size; centrally located nuclei, split and fused fibres, inflammatory cell infiltration and myocyte disarray, were apparent in all H&E stained sham-treated mdx muscles ( Figure 5 ). These changes were more pronounced in the diaphragm and intercostal muscles than the latissimus and longissimus dorsi muscles. However, as illustrated in Figure 6 , a lower incidence of centrally nucleated fibres was recorded in AO-treated mdx latissimus muscles (P<0.05) and intercostal muscles (P<0.01), despite the remaining large difference still present between the frequency of centrally nucleated myocytes in these treated mdx and C57 muscles (P<0.001).
Western blots & Immunofluorescence
Western blot analysis of C57 lumbar muscles showed full-length dystrophin at the predicted position (427 kDa), however dystrophin was not detected using this method in AO treated mdx muscles (data not shown). However, when longissimus muscles from AO treated mdx were examined more specifically using immunofluorescence, clusters of muscle fibres that were positive for dystrophin were observed (Figure 7 ). An average of 450 fibres per longissimus muscle were counted, with sham treated mice revealing 1.4% positive fibers (ie revertant fibers) with an average cluster size of 2.6, whereas longissimus muscles from mdx mice treated with 1 µg of AO had 2.9% positive fibers with an average cluster size of 4.5. To confirm the dose-dependency a further group of 6 age-matched mdx mice were injected with 2 µg of AO and euthanased after 4 weeks and these showed an average of 3.4% positive fibers (P<0.05 compared to sham treated) and an average cluster size of 8.2.
Discussion
Antisense oligonucleotide therapy of DMD is a promising approach to the disease in those boys whose genetic defect is amenable to forced alternative splicing. There are, however, a number of questions raised by this mode of therapy -including the safest and most efficacious route of administration, timing, long-term efficacy, and level of dystrophin expression required to ameliorate symptoms. This study sought to examine several of these issues in the mouse model of DMD.
This project examined the outcomes of monthly AO injections administered into the paraspinal muscles of mdx mice aged from 2-18 months of age. These ages were chosen as, although mdx show the most severe necrosis at weaning age, they continue to experience cycles of degeneration and regeneration throughout life, with gradual development of severe or moderate dystrophy in muscles such as the diaphragm, postural muscles and accessory respiratory muscles (11, 17) . In addition, other important clinical features of DMD such as thoracolumbar deformity are seen in mdx mice by 18 months of age (10).
AO injections were well tolerated by the mice, and there was no apparent local swelling, loss of appetite or stiffness of gait following monthly treatments. The KI of the AO treated mice tended to be greater than sham injected mice (indicating less kyphosis) at all time points from 8-18 months of age with statistical differences between groups at 10, 12, 16 and 18 months of age. The KI of AO treated mdx mice tended to plateau from 12-18 months of age, but at 18 months of age was significantly indistinguishable from C57 mice. It can be concluded that 1µg AO injections into paraspinal muscles significantly attenuated thoracic deformity as indicated by an increase in the KI.
It was assumed that the increase in KI may be due to an improvement in muscle function in the mdx mice treated with AOs. However, there was no significant difference in force production in the latissimus dorsi, intercostal or diaphragm muscles from AOtreated mdx compared to sham-treated mdx. There are several possible explanations to account for this. The contribution of each muscle in causing or preventing kyphosis has not been clearly defined, so the role of the latissimus dorsi may not be significant, while the intercostal and diaphragm muscles are unlikely to contribute to reducing kyphosis. It is highly feasible that that the longissimus dorsi is the major muscle contributing to kyphosis, however, it is not possible to conduct whole muscle contractility studies on this muscle so quantitative assessment was not feasible. This point is particularly salient as the longissimus dorsi muscle received the majority of the AO injected. Histology experiments revealed a small but statistically significant decrease in the percentage of fibrosis in the latissimus dorsi and the diaphragm muscles of AO-treated mdx mice. Even though it was assumed that AO therapy would be unlikely to influence fibrosis in the diaphragm muscle, due to lack of direct diaphragm injections, it is possible that reduced contraction-induced injury has occurred as a consequence of the slightly increased thoracic area compared to that observed in the sham treated mdx, as revealed by the increase in KI. This theory is in accordance with other studies on the mdx diaphragm muscle which have stated that the increasing presence of fibrosis as the muscle degenerates may be an adaptive response to prevent overstretch injury (18). This was accompanied by a distribution of some of the ventilatory workload to the accessory respiratory muscles, which ultimately lead to their degeneration also (18). The AO treatment in this study has reduced spinal deformity which should in turn alleviate stress on the diaphragm. It is recognised that stretch of the mdx diaphragm activatives NF B Page 12 of 25 which in turn stimulates inflammatory and profibrotic cytokines (9). Conversely, it is possible that reduced diaphragmatic stress, alleviated by the reduced kyphosis may explain the reduced fibrosis observed in this study.
Evaluation of central nucleation in mdx myocytes has demonstrated the attenuation of dystrophic pathology in other studies, including adeno-associated virus vector-mediated gene therapy (3, 20, 23) and stimulation of calcineurin signalling (2).
The percentage decrease in centrally nucleated fibres of AO treated mdx muscles in this study was statistically significant from untreated muscles, albeit only small. Thus it appears that a high amount of myofibre regeneration is still required to meet the demand of contraction-induced injury in a thoracic cavity that has a non-significant but slightly smaller average area than a C57 mouse. In conclusion, this study provides evidence that long term AO administration reduces muscle pathology in mdx mice, and over a period of 16 months of treatment significantly alters the dystrophic phenotype of kyphosis present in this strain. This benefit is despite low levels of dystrophin expression. However, even greater benefit may be obtained from using higher doses of AOs or using alternative chemistries such as phosphorodiamidate morpholino oligomers, which have a longer duration of action and appear to be more active in vivo (4, 5) . showed significantly greater fibrosis than control mice (column 1). In addition to the dense interstitial collagen network of dystrophin deficient muscle, there was also irregular myocyte size and fibre disarray. In AO treated mice there was a small, but statistically significant decrease in percentage fibrosis of the latissimus dorsi muscles (C) and diaphragm (I) muscles when compared to sham treated mdx. 
